** Shares of heart company Anteris Technologies slide 12.3% to $5.26 in their Nasdaq debut
** Stock opened for trading at $6, valuing the company at $215.6 mln
** AVR sold 14.8 mln shares in its New York IPO at $6/shr to raise $88.8 mln
** Offering priced at a 11.5% discount to the Dec. 5 closing price of its shares on the Australian Securities Exchange
** TD Cowen, Barclays and Cantor were the joint book-running managers for the offering
** AVR will use the proceeds to fund the development of its transcatheter heart valve, among other purposes
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.